Data Supplement

Supplemental Data

• Supplemental Data -

  Supplemental Table 1 - Demographic and clinical details of CRLM patients.

  Supplemental Table 2 - Input parameters for PBPK modelling using Simcyp v18 R1 for alfentanil (predominantly metabolized by CYP3A4), alprazolam (predominantly metabolized by CYP3A4 and CYP3A5), desipramine (predominantly metabolized by CYP2D6), and midazolam (predominantly metabolized by CYP3A4 and CYP3A5).

  Supplemental Table 3 - Protein content (mg/g liver tissue) in homogenates, microsomes, and cytosols from histologically normal and cancerous tissues of CRLM patients.

  Supplemental Table 4 - NADPH cytochrome 450 reductase activities (units/mg tissue) in homogenates and microsomes from histologically normal and tumor tissues of CRLM patients.

  Supplemental Figure 1 - Relationship between observed (current study) and predicted MPPGL values and age (Barter et al., 2008), with 95% confidence intervals for the predicted values for Model 1.